Navigation Links
PDL BioPharma Announces First Quarter 2009 Financial Results
Date:5/7/2009

ties from MedImmune are not included subsequent to the first quarter of 2009 due to ongoing legal activities as discussed above. Revenue growth expectations are primarily driven by increases in product sales of Avastin, Herceptin, Lucentis and Tysabri.

PDL continues to expect its general and administrative expenses for 2009 to range from $12 million to $15 million, of which approximately 50 percent may be related to legal expense, patent defense and other professional fees. Net income after taxes for 2009 continues to be projected in the range of $185 to $200 million and cash generated in 2009 still is expected to be in the range of $260 to $280 million.

Conference Call Details

To access the live conference call today, May 7, 2009 at 4:30 p.m. Eastern Time via phone, please dial (877) 361-8830 from the United States and Canada or (706) 679-8297 internationally. The conference ID is 97783926. Please dial in approximately ten minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through May 14, 2009, and may be accessed by dialing (800) 642-1687 from the United States and Canada or (706) 645-9291 internationally. The replay passcode is 97783926.

To access the live and subsequently archived webcast of the conference call, go to the company's Web site at http://www.pdl.com and click "Investors." Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary.

About PDL BioPharma

PDL BioPharma, Inc. pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and autoimmune diseases. PDL is focused on maximizing the value of our antibody humanization patents and related assets. PDL receives royalties on sales
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Sinobiopharma Secures Rights to Seven Key Patents
2. China Biologic Products Receives $5.3 Million Order from Largest Biopharmaceutical Distributor in India
3. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
4. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
5. Helix BioPharma to Present at the BioFinance 2009 Conference
6. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
7. 2009 Prix Galien USA Now Accepting Nominations for Top Prize in Biopharmaceutical Research and Development
8. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
9. Advanced Instruments Introduces 2020-BIO Multi-Sample Osmometer as First True Automation-Friendly Osmometer for the Biopharmaceutical Industry
10. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
11. Sinobiopharma, Inc. Appoints New Director of Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 Author Matthew J. Pallamary’s second ... Other Side” published as a tribute to his ... “Fiction: Short Story” category of the 2014 USA ... CEO of USA Book News, said this year’s contest ... including Simon & Schuster, Penguin, John Wiley & Sons, ...
(Date:11/21/2014)... The November 2014 issue of BioTechniques ... access journal featuring the following articles:, , ... photoresponsiveness in the retina , DNA from ... using chromogenic substrates in zebrafish , Re-use ... electrophoresis , Nuclear LC3-positive puncta in stressed ...
(Date:11/21/2014)... 21, 2014 2014 Deep Research ... is a professional and in-depth research report on ... information, like its definition, classification, application, and ... This report covers the international market analysis, including ... as the US, Europe, Asia, China, Japan etc. ...
(Date:11/21/2014)... 20, 2014 /CNW/ - Aequus Pharmaceuticals Inc. (the ... it has closed a brokered private placement offering ... C$3.7 million.  Cormark Securities Inc. and Clarus Securities ... Offering for a syndicate of agents that also ... (collectively the "Agents"). Concurrently with the Brokered Offering, ...
Breaking Biology Technology:Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3
... (Nasdaq: KNDL ) a,leading, global full-service clinical ... the annual Raymond James,Boston Fall Investors Conference. The conference ... 33rd floor, in Boston on Dec. 11, 2008. Kendle,s,presentation ... Time. , (Logo: ...
... BioMarin Pharmaceutical,Inc. (Nasdaq: BMRN ) ... a division,of Merck KGaA, Darmstadt, Germany, has ... the treatment of,hyperphenylalaninemia (HPA) in phenylketonuria (PKU) ... Merck Serono estimates that there are,approximately ...
... Delcath Systems, Inc. (Nasdaq: DCTH ) today announced the ... Dr. Stoll is Executive Chairman of Cortex Pharmaceuticals, Inc. (Amex: ... of central nervous system disorders. , ... , Prior to joining Cortex, Dr. Stoll ...
Cached Biology Technology:Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference 2Kuvan Receives Marketing Approval in the European Union 2Kuvan Receives Marketing Approval in the European Union 3Kuvan Receives Marketing Approval in the European Union 4Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors 2Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors 3
(Date:11/4/2014)... SALT LAKE CITY, Nov. 5, 2014 – University of ... uses enzymes to help jet fuel produce electricity without ... can be used to power portable electronics, off-grid power ... appears online today in the American Chemical Society journal ... into electricity through a chemical reaction between a fuel ...
(Date:11/4/2014)... England , November 4, 2014 ... and vertical market growth   Fuel3D , ... has closed a funding round totaling $6.4 million (£4 million). ... million) funding secured earlier this year and paves the way ... in 2015. The funding round was led by ...
(Date:11/3/2014)... , Nov. 3, 2014  NeuroSigma ® ... -based life sciences company focused on commercialization of ... for the treatment of neurological and neuropsychiatric ... Industrial Property has issued a Notice of Allowance ... application is co-owned by NeuroSigma and the Regents ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... -- Tiny electrical wires protrude from some bacteria and ... protein that makes up one such wire have determined ... diverse fields as producing energy, recycling Earth,s carbon and ... structure of this protein from an electrically conductive bacterial ...
... A new multi-million dollar collaboration will enable ... the data-rich world that characterizes all fields of ... New York University, the University of California, Berkeley ... within and across the three campuses and other ...
... Spring Harbor Laboratory (CSHL) today announced the launch of a ... a new, free service, called bioRxiv (pronounced "bio-Archive"). It ... the results of their work before peer review and publication ... contents costs nothing. Each paper is given a citable ...
Cached Biology News:Structure of bacterial nanowire protein hints at secrets of conduction 2Structure of bacterial nanowire protein hints at secrets of conduction 3Bold new partnership launches to harness potential of data scientists and big data 2Bold new partnership launches to harness potential of data scientists and big data 3Bold new partnership launches to harness potential of data scientists and big data 4CSHL launches bioRxiv, a freely accessible, citable preprint server for biology 2
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
... Water is suitable for use ... by incubating with 0.1% diethylpyrocarbonate ... remove the DEPC.DNase/RNase-Free Distilled WaterDistilled ... in all molecular biology applications. ...
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
The Hybrid Hunter Yeast Two-Hybrid System uses the activation of reporter genes to indicate positive protein-protein interactions. Two reporters are used an auxotrophic marker and lacZ....
Biology Products: